Article citationsMore>>

Gibson, M.K., Li, Y., Murphy, B., Hussain, M.H., DeConti, R.C., Ensley, J., et al. (2005) Randomized Phase III Evaluation of Cisplatin plus Fluorouracil versus Cisplatin plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23, 3562-3567.
http://dx.doi.org/10.1200/JCO.2005.01.057

has been cited by the following article:

• TITLE: Chemotherapeutic Effect of Withaferin A in Human Oral Cancer Cells

  AUTHORS: In-Hyoung Yang, Lee-Han Kim, Ji-Ae Shin, Sung-Dae Cho

  KEYWORDS: Oral Cancer, Withaferin A, Apoptosis, Bim, Bax

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.8, August 10, 2015

  ABSTRACT: Withaferin A (WA) is a bioactive compound derived from a medicinal plant Withania somnifera and has potential therapeutic effects against various types of cancers. The purpose of this study is to investigate an apoptotic effect of WA and identify its molecular target in HSC-3 and HSC-4 human oral cancer cell lines using Trypan blue exclusion assay, DAPI staining and western blotting. WA inhibited cell viability and induced apoptosis in a concentration- or time-dependent manner, as evidenced by induction of nuclear condensation and fragmentation, activation of caspase 3 and poly (ADP-ribose) polymerase (PARP) cleavage. WA-induced apoptosis was partly diminished by Z-VAD, a pancaspase inhibitor. WA also increased Bim and Bax protein in HSC-3 and HSC-4 cells, respectively. These results suggest that WA may be a potential chemotherapeutic drug candidate against human oral cancer.